Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
- PMID: 37914475
- DOI: 10.1016/S2352-3026(23)00235-1
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
Conflict of interest statement
ATF reports consultation fees for Astellas, Bristol-Myers Squibb, Takeda, AbbVie Genentech, Daiichi Sankyo, PureTech, Pfizer, Rigel, Gilead, Amgen, Remix, Orum, Menarini, Ipsen, and clinical trial research grant support from Servier, Bristol-Myers Squibb, and AbbVie.
Comment on
-
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.Lancet Haematol. 2023 Nov;10(11):e902-e912. doi: 10.1016/S2352-3026(23)00207-7. Lancet Haematol. 2023. PMID: 37914483 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials